Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $33.03M
• Dividend Yield: N/A
• Average Volume (3M): 94.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: -100.00%
• EPS Growth: -26.30%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 40,830,353
• 10 Day Avg. Volume: 123,502
• 30 Day Avg. Volume: 94,050
• PEG Ratio: 0.04
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 3.18
• P/FCF Ratio: -1.60
• Enterprise Value/Market Cap: -0.40
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: $3.00
• Price Target Upside: 118.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.63
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.00 ▼(-27.01% Downside)

Barinthus Biotherapeutics faces significant financial and technical challenges. The company's ongoing losses and negative cash flows are major concerns, compounded by bearish technical indicators and a negative P/E ratio. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Strategic Merger

The merger with Clywedog Therapeutics diversifies Barinthus's pipeline and enhances its market position in metabolic and autoimmune diseases, potentially leading to a stronger, more resilient company structure.

Pipeline Diversification

Diversifying the pipeline with clinical-stage candidates in key therapeutic areas strengthens Barinthus's competitive advantage and market reach, potentially leading to sustainable revenue growth.

Improved Gross Margin

Improved gross margins suggest effective cost control and operational efficiency, which can enhance profitability and financial stability over the long term.

Negative Factors

Ongoing Losses

Persistent losses and negative cash flows indicate financial instability, which could hinder the company's ability to invest in R&D and growth initiatives, impacting long-term viability.

Liquidity Issues

Liquidity issues from negative cash flows could limit Barinthus's ability to meet short-term obligations and fund strategic initiatives, posing a risk to its financial health.

Revenue Volatility

Revenue volatility can create uncertainty in financial planning and investor confidence, potentially affecting the company's ability to secure funding and sustain growth.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics (BRNS) is a biotechnology company focused on the development and commercialization of innovative biotherapeutic solutions. Operating primarily in the healthcare sector, BRNS specializes in creating advanced therapies for chronic and rare diseases through its proprietary platform that leverages cutting-edge genetic and molecular technologies. The company aims to address unmet medical needs by providing targeted treatment options that improve patient outcomes and enhance the quality of life.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue through multiple key streams, primarily from the sale of its biotherapeutic products, which are developed for specific medical conditions. The company also engages in collaborative partnerships with larger pharmaceutical firms, which may involve licensing agreements, co-development deals, and research funding. Additionally, BRNS may receive milestone payments and royalties based on the successful advancement of its products through various stages of clinical development and eventual commercialization. Grants and government funding for research initiatives further supplement the company's earnings, enabling it to innovate and expand its product pipeline.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics is experiencing financial challenges with ongoing losses and negative cash flows, despite improvements in revenue and gross profit margins. The balance sheet is stable, but the company needs to achieve profitability and improve cash flow for long-term sustainability.

Income Statement

Barinthus Biotherapeutics has shown significant volatility in its revenue and profitability. The revenue growth from 2023 to 2024 was substantial, but the company remains unprofitable with negative net income and EBIT margins. The gross profit margin improved in 2024, indicating better cost management, but the overall financial health is hindered by persistent losses.

Balance Sheet

The company's balance sheet reflects a strong equity position with a high equity ratio, indicating stability. However, the debt-to-equity ratio is relatively low, suggesting manageable leverage. The decline in stockholders' equity over the years is a concern, but the reduction in total liabilities is a positive sign.

Cash Flow

Cash flow analysis reveals challenges with negative operating and free cash flows, indicating potential liquidity issues. The free cash flow has improved slightly from 2023 to 2024, but the company continues to burn cash, which could be a risk if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	0.00	14.97M	802.00K	44.70M	268.00K	-9.57M
EBITDA	-69.35M	-55.37M	-71.06M	5.19M	-47.87M	-16.56M
Net Income	-75.88M	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	109.20M	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	74.27M	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	11.57M	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	24.64M	30.19M	27.51M	27.00M	28.15M	53.81M
Stockholders Equity	84.47M	130.03M	186.78M	242.90M	252.13M	-3.54M
Cash Flow
Free Cash Flow	-30.97M	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-30.65M	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	136.00K	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	839.00K	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.22, and above the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 28.95 is Positive, neither overbought nor oversold. The STOCH value of 10.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	43 Neutral	$33.03M	―	-62.30%	―	-100.00%	-26.30%
GDTC	41 Neutral	$22.65M	―	-42.29%	―	―	-21.99%
BOLD	40 Underperform	$27.76M	―	-44.88%	―	―	-0.50%
ALXO	39 Underperform	$78.18M	-0.66	-118.95%	―	―	31.98%
CLGN	38 Underperform	$28.23M	-1.97	-78.25%	―	248.62%	26.22%
ALGS	38 Underperform	$44.35M	-0.36	-141.82%	―	-55.88%	6.14%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Reports Q3 2025 Earnings

Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for autoimmune and inflammatory diseases, operating primarily in the immunology and inflammation sector. The company recently released its earnings report for the quarter ended September 30, 2025, highlighting significant financial and strategic developments. Key financial metrics from the report indicate a challenging quarter for Barinthus Biotherapeutics, with the company reporting a net loss of $14.6 million for the three months ended September 30, 2025, compared to a net loss of $8.1 million in the same period last year. The company’s total revenue for the quarter was nil, down from $14.9 million in the previous year, primarily due to the absence of license revenue. Operating expenses were reduced to $15.2 million from $24.6 million, reflecting a strategic shift in focus. The company also announced a merger agreement with Clywedog Therapeutics, which is expected to enhance its strategic position in the market. Looking ahead, Barinthus Biotherapeutics remains focused on its strategic merger with Clywedog Therapeutics and is committed to advancing its lead candidate, VTP-1000, in clinical trials. The company’s management remains optimistic about future opportunities, despite the current financial challenges.

Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial

Barinthus Biotherapeutics Plc is conducting a Phase 1 clinical trial titled ‘A Phase 1, First in Human, Randomized, Placebo-controlled Trial With a Controlled Gluten Challenge to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VTP-1000 in Adults With Celiac Disease.’ The study aims to assess the safety and tolerability of VTP-1000, a novel treatment for celiac disease, by evaluating its effects on the immune system when administered at various doses.

Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics

On September 29, 2025, Barinthus Biotherapeutics and Clywedog Therapeutics entered into a merger agreement to form a combined entity named Clywedog Therapeutics, Inc. The merger, expected to close in the first half of 2026, will create a company with a diversified pipeline targeting metabolic and autoimmune diseases, including Type 1 and Type 2 diabetes and celiac disease. The transaction will result in Clywedog stockholders owning approximately 66% and Barinthus shareholders owning about 34% of the new company. The combined company will be supported by existing cash and additional investments from OrbiMed and Torrey Pines Investment LLC, and is expected to trade on NASDAQ under the symbol ‘CLYD’.

The most recent analyst rating on (BRNS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.